Trial Court Judgement for Amneal in Litigation over Hyperparathyroidism Drug

Represented Amneal Pharmaceuticals LLC in a Hatch-Waxman patent litigation through trial concerning a drug for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis. Secured judgment of non-infringement from District Court after five-day trial. Amgen Inc. v. Amneal Pharms. LLC, 16-0853-GMS (consolidated) (D. Del.). The Federal Circuit reversed and remanded for further proceedings in the trial court.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.
Disclaimer
Back to Top